Updated by NDF staff on 2nd September, 2024
Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, Therapeutic Innovation Australia (TIA), Phenomics Australia and ANSTO support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.
To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a competitive voucher-style scheme that can subsidise the cost of access to a full range of advanced capabilities. In this Pipeline Accelerator round, TIA is partnering with Phenomics Australia and ANSTO’s National Deuteration Facility (NDF) to expand the list of translation expertise necessary for the discovery and translation of medical research.
In this round, the National Deuteration Facility (NDF) is accessible via applications to other NCRIS facilities that will also require NDF services. Select “Stable Isotope Labelling” box in the online application and provide a quote for services with supporting documentation. For example, if your project needs to access a deuterated molecule as part of a study on bioavailability of a lead candidate.
Applicant should contact NDF as soon as possible (ndf-enquiries@ansto.gov.au) for a feasibility assessment of their request.
Applications to access NDF only (i.e. with no other NCRIS facilities) will not be accepted in this call. These should be made directly through the NDF user program.
The guidelines are available to download below:
Applications for 2024-25 (Round 1) are open and close 5pm (AEST) 31st October, 2024.
Online application
Acknowledgement
The National Deuteration Facility is partly supported by the National Collaborative Research Infrastructure Strategy – an initiative of the Australian Government.
